ORIC Pharmaceuticals Inc. (ORIC)
NASDAQ: ORIC
· Real-Time Price · USD
5.57
-0.14 (-2.45%)
At close: May 01, 2025, 3:59 PM
5.99
7.54%
Pre-market: May 02, 2025, 04:20 AM EDT
-2.45% (1D)
| Bid | 5.29 |
| Market Cap | 395.94M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -127.85M |
| EPS (ttm) | -1.83 |
| PE Ratio (ttm) | -3.04 |
| Forward PE | -2.93 |
| Analyst | Buy |
| Ask | 6 |
| Volume | 499,202 |
| Avg. Volume (20D) | 1,049,562 |
| Open | 5.67 |
| Previous Close | 5.71 |
| Day's Range | 5.35 - 5.75 |
| 52-Week Range | 3.90 - 14.67 |
| Beta | 1.37 |
About ORIC
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; an...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 24, 2020
Employees 115
Stock Exchange NASDAQ
Ticker Symbol ORIC
Website https://www.oricpharma.com
Analyst Forecast
According to 9 analyst ratings, the average rating for ORIC stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 259.07% from the latest price.
Stock Forecasts2 months ago
+2.72%
Oric Pharmaceuticals shares are trading higher. JP...
Unlock content with
Pro Subscription
6 months ago
-0.42%
Oric Pharmaceuticals shares are trading higher after Jones Trading initiated coverage on the stock with a Buy rating and announced a price target of $17.
